Telomir Pharmaceuticals Inc (TELO)
6.01
-0.17
(-2.78%)
USD |
NASDAQ |
May 17, 16:00
6.42
+0.41
(+6.82%)
After-Hours: 20:00
Telomir Pharmaceuticals Cash from Financing (TTM): 8.336M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.336M |
| Date | Value |
|---|---|
| December 31, 2023 | 3.860M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.860M
Minimum
Dec 2023
8.336M
Maximum
Mar 2024
6.098M
Average
6.098M
Median
Cash from Financing (TTM) Benchmarks
| Bio-Path Holdings Inc | -- |
| Hepion Pharmaceuticals Inc | 4.495M |
| Annexon Inc | 150.36M |
| Inhibikase Therapeutics Inc | 8.405M |
| Chromocell Therapeutics Corp | 1.140M |